BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 30139575)

  • 1. Structure-based design and synthesis of 1H-pyrazolo[3,4-d]pyrimidin-4-amino derivatives as Janus kinase 3 inhibitors.
    Yin Y; Chen CJ; Yu RN; Wang ZJ; Zhang TT; Zhang DY
    Bioorg Med Chem; 2018 Sep; 26(17):4774-4786. PubMed ID: 30139575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based design and synthesis of pyrimidine-4,6-diamine derivatives as Janus kinase 3 inhibitors.
    Yu RN; Chen CJ; Shu L; Yin Y; Wang ZJ; Zhang TT; Zhang DY
    Bioorg Med Chem; 2019 Apr; 27(8):1646-1657. PubMed ID: 30853331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel 1H-pyrazolo[3,4-d]pyrimidin-6-amino derivatives as potent selective Janus kinase 3 (JAK3) inhibitors. Evaluation of their improved effect for the treatment of rheumatoid arthritis.
    Yin Y; Chen CJ; Yu RN; Shu L; Wang ZJ; Zhang TT; Zhang DY
    Bioorg Chem; 2020 May; 98():103720. PubMed ID: 32171982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel selective Janus kinase 2 (JAK2) inhibitors bearing a 1H-pyrazolo[3,4-d]pyrimidin-4-amino scaffold.
    Yin Y; Chen CJ; Yu RN; Shu L; Zhang TT; Zhang DY
    Bioorg Med Chem; 2019 Apr; 27(8):1562-1576. PubMed ID: 30846405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3.
    Nakajima Y; Inoue T; Nakai K; Mukoyoshi K; Hamaguchi H; Hatanaka K; Sasaki H; Tanaka A; Takahashi F; Kunikawa S; Usuda H; Moritomo A; Higashi Y; Inami M; Shirakami S
    Bioorg Med Chem; 2015 Aug; 23(15):4871-4883. PubMed ID: 26071372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and pharmacological evaluation of 4- or 6-phenyl-pyrimidine derivatives as novel and selective Janus kinase 3 inhibitors.
    Shu L; Chen C; Huan X; Huang H; Wang M; Zhang J; Yan Y; Liu J; Zhang T; Zhang D
    Eur J Med Chem; 2020 Apr; 191():112148. PubMed ID: 32097841
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Faris A; Hadni H; Saleh BA; Khelfaoui H; Harkati D; Ait Ahsaine H; Elhallaoui M; El-Hiti GA
    J Biomol Struct Dyn; 2024 Jun; 42(9):4456-4474. PubMed ID: 37317996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico discovery of potent and selective Janus kinase 3 (JAK3) inhibitors through 3D-QSAR, covalent docking, ADMET analysis, molecular dynamics simulations, and binding free energy of pyrazolopyrimidine derivatives.
    Faris A; Hadni H; Ibrahim IM; Elhallaoui M
    J Biomol Struct Dyn; 2024 Jun; 42(9):4817-4833. PubMed ID: 37338041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and Synthesis of a Highly Selective JAK3 Inhibitor for the Treatment of Rheumatoid Arthritis.
    He L; Pei H; Lan T; Tang M; Zhang C; Chen L
    Arch Pharm (Weinheim); 2017 Nov; 350(11):. PubMed ID: 28944566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and SAR study of highly potent, selective, irreversible covalent JAK3 inhibitors.
    He L; Shao M; Wang T; Lan T; Zhang C; Chen L
    Mol Divers; 2018 May; 22(2):343-358. PubMed ID: 29411195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and preliminary biological evaluation of 4-aminopyrazole derivatives as novel and potent JAKs inhibitors.
    Liang X; Huang Y; Zang J; Gao Q; Wang B; Xu W; Zhang Y
    Bioorg Med Chem; 2016 Jun; 24(12):2660-72. PubMed ID: 27137359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2(1H)-one derivatives as novel JAK inhibitors.
    Yamagishi H; Shirakami S; Nakajima Y; Tanaka A; Takahashi F; Hamaguchi H; Hatanaka K; Moritomo A; Inami M; Higashi Y; Inoue T
    Bioorg Med Chem; 2015 Aug; 23(15):4846-4859. PubMed ID: 26059596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket.
    Forster M; Chaikuad A; Bauer SM; Holstein J; Robers MB; Corona CR; Gehringer M; Pfaffenrot E; Ghoreschi K; Knapp S; Laufer SA
    Cell Chem Biol; 2016 Nov; 23(11):1335-1340. PubMed ID: 27840070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Selective Covalent Janus Kinase 3 Inhibitors.
    Tan L; Akahane K; McNally R; Reyskens KM; Ficarro SB; Liu S; Herter-Sprie GS; Koyama S; Pattison MJ; Labella K; Johannessen L; Akbay EA; Wong KK; Frank DA; Marto JA; Look TA; Arthur JS; Eck MJ; Gray NS
    J Med Chem; 2015 Aug; 58(16):6589-606. PubMed ID: 26258521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of 4-(2-furanyl)pyrimidin-2-amines as Janus kinase 2 inhibitors.
    Wang Y; Huang W; Xin M; Chen P; Gui L; Zhao X; Tang F; Wang J; Liu F
    Bioorg Med Chem; 2017 Jan; 25(1):75-83. PubMed ID: 27771180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease.
    Mahajan S; Hogan JK; Shlyakhter D; Oh L; Salituro FG; Farmer L; Hoock TC
    J Pharmacol Exp Ther; 2015 May; 353(2):405-14. PubMed ID: 25762693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural optimizations on the 7H-pyrrolo[2,3-d]pyrimidine scaffold to develop highly selective, safe and potent JAK3 inhibitors for the treatment of Rheumatoid arthritis.
    He L; Zhang J; Ling Z; Zeng X; Yao H; Tang M; Huang H; Xie X; Qin T; Feng X; Chen Z; Deng F; Yue X
    Bioorg Chem; 2024 Aug; 149():107499. PubMed ID: 38815476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of 4-amino-1H-pyrazolo[3,4-d]pyrimidin derivatives as novel discoidin domain receptor 1 (DDR1) inhibitors.
    Dong R; Zhou X; Wang M; Li W; Zhang JY; Zheng X; Tang KX; Sun LP
    Bioorg Med Chem; 2021 Jan; 29():115876. PubMed ID: 33246255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, evaluation and docking of novel pyrazolo pyrimidines as potent p38α MAP kinase inhibitors with improved anti-inflammatory, ulcerogenic and TNF-α inhibitory properties.
    Somakala K; Tariq S; Amir M
    Bioorg Chem; 2019 Jun; 87():550-559. PubMed ID: 30928877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors.
    Casimiro-Garcia A; Trujillo JI; Vajdos F; Juba B; Banker ME; Aulabaugh A; Balbo P; Bauman J; Chrencik J; Coe JW; Czerwinski R; Dowty M; Knafels JD; Kwon S; Leung L; Liang S; Robinson RP; Telliez JB; Unwalla R; Yang X; Thorarensen A
    J Med Chem; 2018 Dec; 61(23):10665-10699. PubMed ID: 30423248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.